Hamza Kandoussi

674 total citations
25 papers, 556 citations indexed

About

Hamza Kandoussi is a scholar working on Hepatology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Hamza Kandoussi has authored 25 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hepatology, 12 papers in Infectious Diseases and 10 papers in Pharmacology. Recurrent topics in Hamza Kandoussi's work include Hepatitis C virus research (15 papers), HIV/AIDS drug development and treatment (12 papers) and Drug Transport and Resistance Mechanisms (7 papers). Hamza Kandoussi is often cited by papers focused on Hepatitis C virus research (15 papers), HIV/AIDS drug development and treatment (12 papers) and Drug Transport and Resistance Mechanisms (7 papers). Hamza Kandoussi collaborates with scholars based in United States, Germany and Sweden. Hamza Kandoussi's co-authors include Marc Bifano, Richard Bertz, Carey Hwang, Jianing Zeng, Τushar Garimella, Hao Jiang, Mark E. Arnold, Timothy Eley, Hong Shen and Dennis M. Grasela and has published in prestigious journals such as Analytical Chemistry, Antimicrobial Agents and Chemotherapy and Journal of Hepatology.

In The Last Decade

Hamza Kandoussi

24 papers receiving 544 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hamza Kandoussi United States	15	307	202	197	140	106	25	556
Robert Houle Canada	14	146 0.5×	84 0.4×	123 0.6×	235 1.7×	136 1.3×	26	577
Xiao‐Jian Zhou United States	19	282 0.9×	475 2.4×	318 1.6×	111 0.8×	49 0.5×	44	1.0k
Brian Grabowski United States	10	90 0.3×	340 1.7×	68 0.3×	64 0.5×	99 0.9×	14	731
Chan‐Loi Yong United States	13	432 1.4×	260 1.3×	400 2.0×	88 0.6×	37 0.3×	22	944
Michelle Bentata France	10	125 0.4×	308 1.5×	170 0.9×	74 0.5×	136 1.3×	16	616
Rucha Sane United States	14	66 0.2×	124 0.6×	68 0.3×	305 2.2×	284 2.7×	36	713
Pauline Hall Australia	11	114 0.4×	71 0.4×	198 1.0×	88 0.6×	116 1.1×	18	569
Cecil L. Hornbeck United States	15	212 0.7×	131 0.6×	135 0.7×	88 0.6×	22 0.2×	26	634
Gerry Rhodes United States	11	72 0.2×	434 2.1×	145 0.7×	80 0.6×	67 0.6×	21	709
John P. Sabo United States	16	84 0.3×	555 2.7×	126 0.6×	136 1.0×	150 1.4×	34	919

Countries citing papers authored by Hamza Kandoussi

Since Specialization

Citations

This map shows the geographic impact of Hamza Kandoussi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hamza Kandoussi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hamza Kandoussi more than expected).

Fields of papers citing papers by Hamza Kandoussi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hamza Kandoussi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hamza Kandoussi. The network helps show where Hamza Kandoussi may publish in the future.

Co-authorship network of co-authors of Hamza Kandoussi

This figure shows the co-authorship network connecting the top 25 collaborators of Hamza Kandoussi. A scholar is included among the top collaborators of Hamza Kandoussi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hamza Kandoussi. Hamza Kandoussi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Yueping, Vinay K. Holenarsipur, Hamza Kandoussi, et al.. (2020). Detection of Weak Organic Anion–Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans. Drug Metabolism and Disposition. 48(10). 841–848. 26 indexed citations

Shen, Hong, Lisa J. Christopher, Yurong Lai, et al.. (2018). Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition. Drug Metabolism and Disposition. 46(8). 1075–1082. 50 indexed citations

Kandoussi, Hamza, Weiqi Chen, Naiyu Zheng, et al.. (2018). LC–MS/MS Bioanalysis of Plasma 1, 14-Tetradecanedioic Acid and 1, 16-Hexadecanedioic Acid as Candidate Biomarkers for Organic Anion-Transporting Polypeptide Mediated Drug–Drug Interactions. Bioanalysis. 10(18). 1473–1485. 6 indexed citations

Garimella, Τushar, Xiaoli You, Shu‐Pang Huang, et al.. (2016). A Review of Daclatasvir Drug–Drug Interactions. Advances in Therapy. 33(11). 1867–1884. 21 indexed citations

Yuan, Long, Yi Luo, Hamza Kandoussi, & Qin Ji. (2016). A Simple, Fast, Sensitive and Robust LC-MS/MS Bioanalytical Assay for Evaluating 7α-Hydroxy-4-Cholesten-3-One Biomarker in A Clinical Program. Bioanalysis. 8(23). 2445–2455. 11 indexed citations

Shen, Hong, Hualiang Jiang, Craig Titsch, et al.. (2015). Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo Evaluation. Drug Metabolism and Disposition. 44(2). 238–249. 29 indexed citations

Kandoussi, Hamza, Hao Jiang, Jianing Zeng, et al.. (2015). A highly sensitive and selective LC–MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis. 119. 145–151. 7 indexed citations

Jiang, Hao, Hamza Kandoussi, Jianing Zeng, et al.. (2015). Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 107. 409–418. 60 indexed citations

Bifano, Marc, et al.. (2015). An Open-Label Investigation into Drug–Drug Interactions Between Multiple Doses of Daclatasvir and Single-Dose Cyclosporine or Tacrolimus in Healthy Subjects. Clinical Drug Investigation. 35(5). 281–289. 28 indexed citations

10.

Eley, Timothy, Shu‐Pang Huang, Bing He, et al.. (2014). The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus. Clinical Drug Investigation. 34(9). 661–671. 17 indexed citations

11.

Garimella, Τushar, Wen‐Lin Luo, Philip Wastall, et al.. (2014). Evaluation of drug‐drug interaction between daclatasvir and methadone or buprenorphine/naloxone. Journal of the International AIDS Society. 17(4S3). 19628–19628. 5 indexed citations

12.

Jiang, Hao, Hamza Kandoussi, Richard C. Burrell, et al.. (2014). Sensitive and accurate liquid chromatography–tandem mass spectrometry methods for quantitative determination of a novel hepatitis C NS5B inhibitor BMS-791325 and its active metabolite in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 107. 17–23. 5 indexed citations

13.

Garimella, Τushar, Hamza Kandoussi, Michael Hesney, et al.. (2014). 822Effect of Steady State Daclatasvir Plus Asunaprevir on the Single Dose Pharmacokinetics of the P-glycoprotein Substrate Digoxin in Healthy Adult Subjects. Open Forum Infectious Diseases. 1(suppl_1). S235–S235. 4 indexed citations

14.

Garimella, Τushar, Wen‐Lin Luo, Carey Hwang, et al.. (2014). The Effect of Renal Impairment on Single-Dose Pharmacokinetics of Daclatasvir, an HCV NS5A Inhibitor. The American Journal of Gastroenterology. 109. S170–S171. 5 indexed citations

15.

Garimella, Τushar, Wen‐Lin Luo, Carey Hwang, et al.. (2014). Single-Dose Pharmacokinetics and Safety of Daclatasvir in Subjects with Renal Function Impairment. Antiviral Therapy. 20(5). 535–543. 40 indexed citations

16.

Huang, Shu‐Pang, Biao He, Ellen Chung, et al.. (2013). 451 EVALUATION OF PHARMACOKINETIC DRUG–DRUG INTERACTION (DDI) BETWEEN BMS-791325, AN NS5B NON-NUCLEOTIDE POLYMERASE INHIBITOR, DACLATASVIR AND ASUNAPREVIR IN TRIPLE COMBINATION IN HCV GENOTYPE 1-INFECTED PATIENTS. Journal of Hepatology. 58. S184–S184. 8 indexed citations

17.

Bifano, Marc, Carey Hwang, B. Oosterhuis, et al.. (2013). Assessment of Pharmacokinetic Interactions of the HCV Ns5A Replication Complex Inhibitor Daclatasvir with Antiretroviral Agents: Ritonavir-Boosted Atazanavir, Efavirenz and Tenofovir. Antiviral Therapy. 18(7). 931–940. 70 indexed citations

18.

Jiang, Hao, Jianing Zeng, Wenying Li, et al.. (2012). Practical and Efficient Strategy for Evaluating Oral Absolute Bioavailability with an Intravenous Microdose of a Stable Isotopically-Labeled Drug Using a Selected Reaction Monitoring Mass Spectrometry Assay. Analytical Chemistry. 84(22). 10031–10037. 34 indexed citations

19.

Jiang, Hao, Jianing Zeng, Hamza Kandoussi, et al.. (2012). A sensitive and accurate liquid chromatography–tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine. Journal of Chromatography A. 1245. 117–121. 33 indexed citations

20.

Jiang, Hao, Jianing Zeng, Naiyu Zheng, et al.. (2011). A Convenient Strategy for Quantitative Determination of Drug Concentrations in Tissue Homogenates Using a Liquid Chromatography/Tandem Mass Spectrometry Assay for Plasma Samples. Analytical Chemistry. 83(16). 6237–6244. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact